 risk myelodysplasia leukaemia etoposide cisplatin bleomycin germ-cell tumours cytostatic drugs agents leukaemogenic report cases acute myeloid leukaemia myelodysplasia cohort patients germ-cell tumours etoposide cisplatin bleomycin mean cumulative risk leukaemic complications SE years start etoposide-containing chemotherapy risk general population relative risk overt leukaemia CI leukaemias previous cohort patients germ-cell tumours cisplatin bleomycin vinblastine increased risk leukaemia due combination cisplatin bleomycin work excess leukaemias patients germ-cell tumours cisplatin bleomycin vinblastine risk leukaemia patients leukaemic complications cumulative dose etoposide leukaemias patients leukaemic patients chromosome translocations bands translocations aberrations characteristic myelodysplasia acute leukaemia therapy cytostatic agents DNA-topoisomerase II